NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE175761 Query DataSets for GSE175761
Status Public on May 29, 2021
Title Drug Combination Signatures for Prediction and Mitigation of Toxicity [single cell]
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Summary Single cell transcriptomic signatures of cardiomyocytes differentiated from hiPSC lines generated from clinically well-characterized, diverse healthy human individuals. We provide single cell mRNAseq data of cardiomyocytes differentiated from 4 hiPSC lines.
 
Overall design The overall goal of the drug signatures for prediction and mitigation of toxicity study is to use genomic and proteomic high-throughput measurements as the basis for computational analysis that integrates network analyses with structural constraints and dynamical models in multiple cell types to identify signatures that predict toxicity induced by 55 FDA-approved chemotherapeutic drugs and potential mitigation of this toxicity. For this purpose, we have generated human induced pluripotent cell (hiPSC) lines from established fibroblast lines of forty clinically healthy racially diverse male and female study participants who ranged in age from 22 and 61 years. One clone from each of the forty hiPSC line was fully characterized for normal karyotype, short-tandem repeat matching to the original fibroblast line (authentication), pluripotency by select pluripotent marker expression via immunocytochemistry and by mRNAseq-based PluriTest analysis, and whole-genome sequencing. In order to establish singel cell transcriptomic signatures specific to clinically well-characterized healthy individuals, cardiomyocytes were differentiated from four hiPSC lines derived from 2 male and 2 female, age matched (23 and 33 yrs old, and 24 and 36 yrs old, respectively) persons using an established protocol, purified to 95% purity (SIRPA+CD90-) using a metabolic switch protocol, reseeded and treated for 24 hrs with DMSO (14.1mM) before single cell mRNAseq was performed using the 10x Genomics platform.
 
Citation(s) 34739849, 39261481
Submission date May 28, 2021
Last update date Oct 09, 2024
Contact name Ravi Iyengar
Organization name Icahn School of Medicine at Mount Sinai
Department Pharmacological Sciences
Street address 1425 Madison Avenue, Room 12-70C
City New York
State/province NY
ZIP/Postal code 10029
Country USA
 
Platforms (1)
GPL24676 Illumina NovaSeq 6000 (Homo sapiens)
Samples (4)
GSM5346014 Control MSN01-03R-CM Rep 1
GSM5346015 Control MSN02-04R-CM Rep 1
GSM5346016 Control MSN08-13R-CM Rep 1
Relations
BioProject PRJNA733493
SRA SRP321795

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE175761_Genenrate-iPSC-CM-scRNA-Ensembl-Gene-Counts-Table.GEO.R.gz 907 b (ftp)(http) R
GSE175761_RAW.tar 339.9 Mb (http)(custom) TAR (of TAR, TSV)
SRA Run SelectorHelp
Raw data are available in SRA
Processed data provided as supplementary file

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap